Biotechnology Events


Allergan/Serenity Pharmaceuticals, LLC Desmopressin FDA Advisory Committee Meeting

10/19/2016 - 08:15
10/19/2016 - 17:00


October 19, 2016: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee

Center Date Time Location
CDER October 19, 2016 8:15 a.m. to 5:00 p.m. FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
The Great Room (Rm. 1503)
Silver Spring, Maryland

The committee will discuss the efficacy and safety of new drug application (NDA) 201656 (desmopressin), 0.75 mcg/0.1 mL and 1.5 mcg/0.1 mL nasal spray, submitted by Serenity Pharmaceuticals, LLC, for the proposed treatment of adult onset nocturia.

Meeting Materials

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at: 2016 Meeting Materials, Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Advisory Committee for Reproductive Health Drugs (ACRHD))

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committees.

Written submissions may be made to the contact person on or before October 4, 2016.
Oral presentations from the public will be scheduled between approximately 1:00 p.m. to 2:00 p.m. on October 19, 2016. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 26, 2016.
Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by September 27, 2016.

Webcast Information

CDER plans to provide a free of charge, live webcast of the October 19, 2016, meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee. While CDER is working to make webcasts available to the public for all advisory committee meetings held at the White Oak campus, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible. Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: 2016 Meeting Materials, Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Advisory Committee for Reproductive Health Drugs (ACRHD)).

CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.

Contact Information

Kalyani Bhatt
Center for Drug Evalulation and Research
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, Maryland 20993-0002
Telephone: (301) 796-9001
Fax: (301) 847-8533
FDA Advisory Committee Information Line
(301-443-0572 in the Washington DC area)
Please call the Information Line for up-to-date information on this meeting